샘플 요청 목록

 카트 문의
시장보고서
상품코드
1469104

염증성 장질환(IBD) 치료제 시장(2024-2034년)

Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034
발행일: | 리서치사: Visiongain | 페이지 정보: 영문 318 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 염증성 장질환(IBD) 치료제 시장 규모는 2034년까지 연평균 6.2%의 성장률을 보일 것으로 예상됩니다.

IBD 발병률 상승으로 시장 수요 증가:

IBD의 전 세계 유병률과 유병률은 선진국과 개발도상국 간에 현저한 차이가 있지만, 증가 추세에 있습니다. 크론병과 궤양성 대장염은 서유럽식 식습관과 생활습관이 원인일 수 있기 때문에 선진국에서 더 많이 발생합니다. 급속한 도시화도 IBD를 포함한 자가면역질환의 증가에 기여하고 있습니다. 유럽과 미국에서는 발병률이 안정된 것으로 보이지만, 신흥국에서는 발병률이 증가하고 있는데, 이는 서유럽화와 질병에 대한 인식이 높아졌기 때문일 수 있습니다. 최근 연구에 따르면, 특히 이전에는 발병률이 낮았던 지역에서 발병률이 증가하고 있습니다. EFCCA(European Federation of Crohn's and Ulcerative Colitis Associations, 유럽 크론병 및 궤양성 대장염 협회)에 따르면, 2022년에는 전 세계적으로 1,000만 명의 IBD 환자가 발생할 것으로 예상하고 있습니다. 또한 CCFA(Crohn's &Colitis Foundation of America)에 따르면, 미국에서는 매년 7만 명이 새롭게 IBD 진단을 받고, 약 8만 명의 어린이가 IBD에 걸린 것으로 추정되며, 약 160만 명의 미국인이 IBD를 앓고 있는 것으로 보고되고 있습니다. 대부분 35세 이전에 진단을 받은 것으로 보고되고 있습니다.

유전적 요인도 관여하지만, 발병률의 변화에는 환경적 요인의 중요성도 지적되고 있습니다. 사회경제적 변화와 서유럽식 생활양식의 확산이 이러한 증가에 기여하고 있습니다. 대장암과 같은 장외 증상과 합병증은 환자에게 심각한 위험을 초래하며, 치료의 장기적인 영향은 아직 밝혀지지 않았습니다. 소화기 클리닉은 젊은 연령대의 IBD 환자 관리와 동반 질환을 앓고 있는 고령의 환자 관리라는 도전에 직면해 있으며, 이에 대한 신중한 관리 전략이 필요합니다.

IBD 치료제 개발의 큰 성공은 시장 수요를 촉진:

IBD의 진단율이 낮았고, 특히 신흥국들이 그 영향을 많이 받았습니다. 선진국에서도 IBD는 진단이 어려워 오랫동안 정확한 진단이 이루어지지 않았습니다. 그러나 최근 진단법이 개선되면서 환자층이 확대되고, 이에 따라 치료에 대한 수요가 증가하여 시장 수익이 증가하고 있습니다.

세계 염증성 장질환(IBD) 치료제 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 요인 및 시장 기회 분석, 시장 규모 추정 및 예측, 각 부문별·지역별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

  • 주요 조사 결과
  • 시장 역학
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • 시장 기회
  • COVID-19의 영향 분석
  • Porter's Five Forces 분석
  • PEST 분석

제4장 염증성 장질환(IBD) 치료제 시장 분석 : 적응증별

  • 주요 조사 결과
  • 시장 매력 지수
  • 시장 규모 추정과 예측
  • 크론병
  • 궤양성 대장염
    • 시장 규모 추정과 예측 : 지역별
    • 시장 점유율 : 지역별

제5장 염증성 장질환(IBD) 치료제 시장 분석 : 투여 경로별

  • 주요 조사 결과
  • 시장 매력 지수
  • 시장 규모 추정과 예측
  • 경구
  • 비경구
  • 직장
    • 시장 규모 추정과 예측 : 지역별
    • 시장 점유율 : 지역별

제6장 염증성 장질환(IBD) 치료제 시장 분석 : 유통 채널별

  • 주요 조사 결과
  • 시장 매력 지수
  • 시장 규모 추정과 예측
  • 소매 약국
  • E-Commerce 약국
  • 기타
    • 시장 규모 추정과 예측 : 지역별
    • 시장 점유율 : 지역별

제7장 염증성 장질환(IBD) 치료제 시장 분석 : 약제 클래스별

  • 주요 조사 결과
  • 시장 매력 지수
  • 시장 규모 추정과 예측
  • TNF-α 차단제
  • 인테그린 억제제
  • 인터류킨 억제제
  • JAK 억제제
  • S1Ps 모듈레이터
  • 기타
    • 시장 규모 추정과 예측 : 지역별
    • 시장 점유율 : 지역별

제8장 염증성 장질환(IBD) 치료제 시장 분석 : 약제별

  • 주요 조사 결과
  • 시장 매력 지수
  • 시장 규모 추정과 예측
  • Cimzia
  • Entyvio
  • Humira
  • Rinvoq
  • Skyrizi
  • Remicade
  • Simponi
  • Stelara
  • 기타
    • 시장 규모 추정과 예측 : 지역별
    • 시장 점유율 : 지역별

제9장 염증성 장질환(IBD) 치료제 시장 분석 : 지역별

  • 주요 조사 결과
  • 시장 규모 추정과 예측

제10장 북미의 염증성 장질환(IBD) 치료제 시장 분석

제11장 유럽의 염증성 장질환(IBD) 치료제 시장 분석

제12장 아시아태평양의 염증성 장질환(IBD) 치료제 시장 분석

제13장 라틴아메리카의 염증성 장질환(IBD) 치료제 시장 분석

제14장 중동 및 아프리카의 염증성 장질환(IBD) 치료제 시장 분석

제15장 기업 개요

  • 경쟁 상황
  • 전략적 전망
  • AbbVie
  • Johnsons &Johnsons
  • Takeda Pharmaceutical Company Limited
  • Pfizer
  • Novartis AG
  • UCB S.A.
  • Biogen
  • F. Hoffmann-La Roche Ltd
  • Celltrion Corporation
  • Ferring B.V.

제16장 결론과 제안

  • Visiongain에 의한 결론
  • 추천사항
ksm 24.05.07

The global Inflammatory Bowel Diseases (IBD) Drugs market is projected to grow at a CAGR 6.2% by 2034

The Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034: This report is essential for prominent enterprises seeking fresh revenue opportunities, aiming to enhance their comprehension of the industry and its inherent dynamics. It provides valuable insights for firms interested in diversifying across various sectors or expanding their current activities into new geographical areas.

Rise in IBD Incidence to Boost the Demand of IBD Drugs Market

The global incidence and prevalence of Inflammatory Bowel Disease (IBD) are increasing, with marked variations between developed and developing nations. Crohn's disease and ulcerative colitis are more common in developed countries, potentially due to Western diets and lifestyle factors. Rapid urbanization has also contributed to the rise in autoimmune diseases, including IBD. While the incidence appears stable in the West, it is increasing in the developing countries, possibly due to Westernization and improved disease awareness. Recent studies show rising incidence rates, especially in regions with previously low rates. Europe has the highest incidence rates, followed by North America and Asia/Middle East. According to EFCCA (European Federation of Crohn's and Ulcerative Colitis Associations) in 2022 there were 10 million people living with IBD worldwide. While according to CCFA ( Crohn's & Colitis Foundation of America), as many as 70,000 new cases of IBD are diagnosed in the United States each year and estimated that approximately 80,000 children in the U.S. are affected with IBD. The IBD has reported to affect almost 1.6 million Americans, most of whom are diagnosed before the age of 35.

Genetic factors play a role, but changing incidence rates emphasize the significance of environmental factors. Socioeconomic shifts and the spread of Western lifestyle contribute to this rise. Extra intestinal manifestations and complications like colon cancer pose significant risks to patients, with long-term implications of treatment are still being understood. Gastroenterology clinics will face challenges managing both younger IBD patients and an aging population with comorbidities, necessitating careful management strategies.

Significant success in IBD Drug Development to Drive the Market Demand

Previously, the diagnosis rate of Inflammatory Bowel Disease (IBD) was low particularly impacting developing countries. Even in developed nations, diagnosing IBD was challenging, leading to prolonged misdiagnoses for many sufferers. However, recent improvements in diagnostics have expanded the patient pool, consequently driving demand for treatments and boosting market revenue.

There has been a rapid surge in randomized clinical trials for Crohn's disease (CD) and ulcerative colitis (UC) treatments, accompanied by detailed epidemiological studies. Despite initial debates, it's now evident that IBD predominantly affects individuals in industrialized nations, with its incidence on the rise. With the advent of newer technologies, there has been a paradigm shift reported in treatment of IBD. Some of the major recent developments include launch and approval of new drugs for instance:

In February 2024, Pfizer Inc. disclosed that the European Commission (EC) has approved marketing authorization for VELSIPITY (etrasimod) within the European Union for the management of moderately to severely active ulcerative colitis (UC) in patients aged 16 and above. This approval extends to individuals who have shown insufficient response, loss of response, or intolerance to conventional therapy or a biological agent.

In March 2024, Celltrion USA has introduced ZYMFENTRA (infliximab-dyyb), a subcutaneous (SC) version of infliximab, marking a significant advancement in treatment options. ZYMFENTRA stands as the sole subcutaneous infliximab approved by the U.S. Food and Drug Administration (FDA) in 2023.

In July 2023, the launch of Yuflyma (adalimumab-aaty) has been announced by Celltrion USA, presenting patients with a high-concentration (100mg/mL) and citrate-free formulation as an alternative option. Yuflyma is approved for the treatment of eight conditions, which encompass rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.

Additionally, Fiberoptic colonoscopy with biopsies and ileocolonoscopy have transformed the diagnosis of both UC and CD globally, particularly in defining disease extent and severity, consequently helping the patients to manage and control IBD.

What Questions Should You Ask before Buying a Market Research Report?

How is the Inflammatory Bowel Diseases Drugs market evolving?

What is driving and restraining the Inflammatory Bowel Diseases Drugs market?

How will each Inflammatory Bowel Diseases Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Inflammatory Bowel Diseases Drugs submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Inflammatory Bowel Diseases Drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Inflammatory Bowel Diseases Drugs projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Inflammatory

Bowel Diseases Drugs projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Inflammatory Bowel Diseases Drugs market?

Where is the Inflammatory Bowel Diseases Drugs market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Inflammatory Bowel Diseases Drugs market today, and over the next 10 years:

Our 318-page report provides 112 tables and 192 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Inflammatory Bowel Diseases Drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Inflammatory Bowel Diseases Drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Indication Outlook

Crohn's Disease

Ulcerative Colitis

Route of Administration Outlook

Oral

Parenteral

Rectal

Distribution Channel Outlook

Hospital Pharmacy

Retail Pharmacy

E-commerce Pharmacy

Others

Drug Class Outlook

TNF-alpha Blockers

Integrin Blockers

Interleukin Inhibitors

JAK Inhibitors

S1Ps Modulators and Others

Drugs Outlook

Cimzia

Entyvio

Humira

Rinvoq

Skyrizi

Remicade

Simponi

Stelara

Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Inflammatory Bowel Diseases Drugs Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

AbbVie

Biogen

Celltrion Healthcare Co.,Ltd.

F. Hoffmann-La Roche Ltd

Ferring B.V.

Johnsons & Johnsons

Novartis AG

Pfizer

Takeda Pharmaceutical Company Limited

UCB S.A.

Overall world revenue for Inflammatory Bowel Diseases Drugs Market, 2024 to 2034 in terms of value the market will surpass US$29.09 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Inflammatory Bowel Diseases Drugs Market, 2024 to 2034 report help you?

In summary, our 310+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Inflammatory Bowel Diseases Drugs Market, 2024 to 2034 Market, with forecasts for drugs, drug class, indication and route of administration each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 21 key national markets - See forecasts for the Inflammatory Bowel Diseases Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Inflammatory Bowel Diseases Drugs Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Inflammatory Bowel Diseases Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Inflammatory Bowel Diseases Drugs Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Rise in IBD Incidence to Boost the Demand of IBD Drugs Market
      • 3.2.1.2 Significant success in IBD Drug Development to Drive the Market Demand
      • 3.2.1.3 Advancements in Oral Drug Delivery for Inflammatory Bowel Disease
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Lack of Understanding of Disease Aetiology
      • 3.2.2.2 Compliance - Frequent Dosing is Inconvenient
      • 3.2.2.3 Limitations of IBD Drugs - Side Effect Profiles
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Advancements in Biological Drugs to Drive the Market Significantly
      • 3.2.3.2 Rising Opportunities for IBD Drugs in Asian Markets
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis

4 Inflammatory Bowel Diseases Drugs Market Analysis by Indication

  • 4.1 Key Findings
  • 4.2 Indication Segment: Market Attractiveness Index
  • 4.3 Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Indication
  • 4.4 Crohn's Disease
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Ulcerative Colitis
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)

5 Inflammatory Bowel Diseases Drugs Market Analysis by Route of Administration

  • 5.1 Key Findings
  • 5.2 Indication Segment: Market Attractiveness Index
  • 5.3 Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Route of Administration
  • 5.4 Oral
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Parenteral
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Rectal
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)

6 Inflammatory Bowel Diseases Drugs Market Analysis by Distribution Channel

  • 6.1 Key Findings
  • 6.2 Indication Segment: Market Attractiveness Index
  • 6.3 Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Distribution Channel
  • 6.4 Hospital Pharmacy
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Retail Pharmacy
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)
  • 6.6 E-commerce Pharmacy
    • 6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.6.2 Market Share by Region, 2024 & 2034 (%)
  • 6.7 Others
    • 6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.7.2 Market Share by Region, 2024 & 2034 (%)

7 Inflammatory Bowel Diseases Drugs Market Analysis by Drug Class

  • 7.1 Key Findings
  • 7.2 Drug Class Segment: Market Attractiveness Index
  • 7.3 Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drug Class
  • 7.4 TNF-alpha Blockers
    • 7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 Integrin Blockers
    • 7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)
  • 7.6 Interleukin Inhibitors
    • 7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.6.2 Market Share by Region, 2024 & 2034 (%)
  • 7.7 JAK inhibitors
    • 7.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.7.2 Market Share by Region, 2024 & 2034 (%)
  • 7.8 S1Ps Modulators and Others
    • 7.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.8.2 Market Share by Region, 2024 & 2034 (%)

8 Inflammatory Bowel Diseases Drugs Market Analysis by Drugs

  • 8.1 Key Findings
  • 8.2 Drugs Segment: Market Attractiveness Index
  • 8.3 Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drugs
  • 8.4 Cimzia
    • 8.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.4.2 Market Share by Region, 2024 & 2034 (%)
  • 8.5 Entyvio
    • 8.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.5.2 Market Share by Region, 2024 & 2034 (%)
  • 8.6 Humira
    • 8.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.6.2 Market Share by Region, 2024 & 2034 (%)
  • 8.7 Rinvoq
    • 8.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.7.2 Market Share by Region, 2024 & 2034 (%)
  • 8.8 Skyrizi
    • 8.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.8.2 Market Share by Region, 2024 & 2034 (%)
  • 8.9 Remicade
    • 8.9.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.9.2 Market Share by Region, 2024 & 2034 (%)
  • 8.10 Simponi
    • 8.10.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.10.2 Market Share by Region, 2024 & 2034 (%)
  • 8.11 Stelara
    • 8.11.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.11.2 Market Share by Region, 2024 & 2034 (%)
  • 8.12 Others
    • 8.12.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.12.2 Market Share by Region, 2024 & 2034 (%)

9 Inflammatory Bowel Diseases Drugs Market Analysis by Region

  • 9.1 Key Findings
  • 9.2 Regional Market Size Estimation and Forecast

10 North America Inflammatory Bowel Diseases Drugs Market Analysis

  • 10.1 Key Findings
  • 10.2 North America Inflammatory Bowel Diseases Drugs Market Attractiveness Index
  • 10.3 North America Inflammatory Bowel Diseases Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 10.4 North America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Country
  • 10.5 North America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Indication
  • 10.6 North America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Route of Administration
  • 10.7 North America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Distribution Channel
  • 10.8 North America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drug Class
  • 10.9 North America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drugs
  • 10.10 U.S. Inflammatory Bowel Diseases Drugs Market Analysis
  • 10.11 Canada Inflammatory Bowel Diseases Drugs Market Analysis

11 Europe Inflammatory Bowel Diseases Drugs Market Analysis

  • 11.1 Key Findings
  • 11.2 Europe Inflammatory Bowel Diseases Drugs Market Attractiveness Index
  • 11.3 Europe Inflammatory Bowel Diseases Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 11.4 Europe Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Country
  • 11.5 Europe Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Indication
  • 11.6 Europe Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Route of Administration
  • 11.7 Europe Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Distribution Channel
  • 11.8 Europe Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drug Class
  • 11.9 Europe Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drugs
  • 11.10 Germany Inflammatory Bowel Diseases Drugs Market Analysis
  • 11.11 France Inflammatory Bowel Diseases Drugs Market Analysis
  • 11.12 UK Inflammatory Bowel Diseases Drugs Market Analysis
  • 11.13 Italy Inflammatory Bowel Diseases Drugs Market Analysis
  • 11.14 Spain Inflammatory Bowel Diseases Drugs Market Analysis
  • 11.15 Rest of Europe Inflammatory Bowel Diseases Drugs Market Analysis

12 Asia Pacific Inflammatory Bowel Diseases Drugs Market Analysis

  • 12.1 Key Findings
  • 12.2 Asia Pacific Inflammatory Bowel Diseases Drugs Market Attractiveness Index
  • 12.3 Asia Pacific Inflammatory Bowel Diseases Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 12.4 Asia Pacific Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Country
  • 12.5 Asia Pacific Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Indication
  • 12.6 Asia Pacific Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Route of Administration
  • 12.7 Asia Pacific Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Distribution Channel
  • 12.8 Asia Pacific Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drug Class
  • 12.9 Asia Pacific Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drugs
  • 12.10 Japan Inflammatory Bowel Diseases Drugs Market Analysis
  • 12.11 China Inflammatory Bowel Diseases Drugs Market Analysis
  • 12.12 India Inflammatory Bowel Diseases Drugs Market Analysis
  • 12.13 Australia Inflammatory Bowel Diseases Drugs Market Analysis
  • 12.14 South Korea Inflammatory Bowel Diseases Drugs Market Analysis
  • 12.15 Rest of Asia Pacific Inflammatory Bowel Diseases Drugs Market Analysis

13 Latin America Inflammatory Bowel Diseases Drugs Market Analysis

  • 13.1 Key Findings
  • 13.2 Latin America Inflammatory Bowel Diseases Drugs Market Attractiveness Index
  • 13.3 Latin America Inflammatory Bowel Diseases Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 13.4 Latin America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Country
  • 13.5 Latin America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Indication
  • 13.6 Latin America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Route of Administration
  • 13.7 Latin America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Distribution Channel
  • 13.8 Latin America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drug Class
  • 13.9 Latin America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drugs
  • 13.10 Brazil Inflammatory Bowel Diseases Drugs Market Analysis
  • 13.11 Mexico Inflammatory Bowel Diseases Drugs Market Analysis
  • 13.12 Rest of Latin America Inflammatory Bowel Diseases Drugs Market Analysis

14 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Analysis

  • 14.1 Key Findings
  • 14.2 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Attractiveness Index
  • 14.3 Middle East and Africa Inflammatory Bowel Diseases Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 14.4 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Country
  • 14.5 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Indication
  • 14.6 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Route of Administration
  • 14.7 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Distribution Channel
  • 14.8 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drug Class
  • 14.9 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drugs
  • 14.10 GCC Inflammatory Bowel Diseases Drugs Market Analysis
  • 14.11 South Africa Inflammatory Bowel Diseases Drugs Market Analysis
  • 14.12 Rest of MEA Inflammatory Bowel Diseases Drugs Market Analysis

15 Company Profiles

  • 15.1 Competitive Landscape, 2023
  • 15.2 Strategic Outlook
  • 15.3 AbbVie
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Financial Analysis
      • 15.3.3.1 Net Revenue, 2018-2022
      • 15.3.3.2 R&D, 2018-2022
      • 15.3.3.3 Regional Market Shares, 2022
    • 15.3.4 Product Benchmarking
    • 15.3.5 Strategic Outlook
  • 15.4 Johnsons & Johnsons
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Financial Analysis
      • 15.4.3.1 Net Revenue, 2018-2022
      • 15.4.3.2 Regional Market Shares, 2022
    • 15.4.4 Product Benchmarking
    • 15.4.5 Strategic Outlook
  • 15.5 Takeda Pharmaceutical Company Limited
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Financial Analysis
      • 15.5.3.1 Net Revenue, 2019-2023
      • 15.5.3.2 R&D, 2019-2023
      • 15.5.3.3 Regional Market Shares, 2022
    • 15.5.4 Product Benchmarking
    • 15.5.5 Strategic Outlook
  • 15.6 Pfizer
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Financial Analysis
      • 15.6.3.1 Net Revenue, 2018-2022
      • 15.6.3.2 R&D, 2018-2022
      • 15.6.3.3 Regional Market Shares, 2022
    • 15.6.4 Product Benchmarking
    • 15.6.5 Strategic Outlook
  • 15.7 Novartis AG
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Financial Analysis
      • 15.7.3.1 Net Revenue, 2018-2022
      • 15.7.3.2 R&D, 2018-2022
      • 15.7.3.3 Regional Market Shares, 2022
    • 15.7.4 Product Benchmarking
    • 15.7.5 Strategic Outlook
  • 15.8 UCB S.A.
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Financial Analysis
      • 15.8.3.1 Net Revenue, 2019-2023
      • 15.8.3.2 R&D, 2019-2023
      • 15.8.3.3 Regional Market Shares, 2023
    • 15.8.4 Product Benchmarking
    • 15.8.5 Strategic Outlook
  • 15.9 Biogen
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Financial Analysis
      • 15.9.3.1 Net Revenue, 2019-2023
      • 15.9.3.2 R&D, 2019-2023
    • 15.9.4 Product Benchmarking
    • 15.9.5 Strategic Outlook
  • 15.10 F. Hoffmann-La Roche Ltd
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Financial Analysis
      • 15.10.3.1 Net Revenue, 2018-2022
      • 15.10.3.2 R&D, 2018-2022
    • 15.10.4 Product Benchmarking
  • 15.11 Celltrion Corporation
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Financial Analysis
      • 15.11.3.1 Net Revenue, 2018-2022
      • 15.11.3.2 R&D, 2018-2022
    • 15.11.4 Product Benchmarking
    • 15.11.5 Strategic Outlook
  • 15.12 Ferring B.V.
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
    • 15.12.3 Product Benchmarking
    • 15.12.4 Strategic Outlook

16 Conclusion and Recommendations

  • 16.1 Concluding Remarks from Visiongain
  • 16.2 Recommendations for Market Players
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제